- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01942811
BiNational Quit Using Drugs Intervention Trial (BiN-QUIT)
2015년 1월 8일 업데이트: Lillian Gelberg, University of California, Los Angeles
US-Mexico Binational Quit Using Drugs Intervention Trial (QUIT)
The goal of the US-Mexico Binational Quit Using Drugs Intervention Trial (QUIT) is a multi-site study conducted in the US (East Los Angeles) and Mexico (Tijuana) which aims to reduce drug demand on both sides of the border.
The study also aims to build a collaborative partnership between the US and Mexico research teams.
The Bi-National QUIT Study will conduct a randomized control trial for risky drug use in several Los Angeles area community health centers.
The intent of the trial is to interrupt the progression to addiction for the casual and occasional users of illicit drugs and non-medical users of pharmaceuticals.
The Bi-National QUIT protocol will include (1) a computerized assessment of the patient's drug-use history (2) very brief (<5 minutes) clinician advice during a patients pre-arranged medical visit which will be preceded by a computerized assessment of the patient's drug-use history (3) a post visit assessment and video doctor (repeating the very brief clinician advice) in the waiting room (4) two post-visit telephone drug-use counseling sessions to be conducted by drug-health educators at approximately 2 and 6 weeks after the start of the intervention.
Follow-up assessments will be conducted at 3 months post-randomization.
Parallel activities will take place in the U.S./Los Angeles sites and Mexico/Tijuana sites.
Data will be shared between both teams.
Data analysis will be collaboratively conducted by both teams.
연구 개요
연구 유형
중재적
등록 (실제)
134
단계
- 해당 없음
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
예
연구 대상 성별
모두
설명
Inclusion Criteria:
US Sites: Inclusion Criteria
Patients
- Adult men and women 18 and older receiving care at the study clinics
- Will be living in the LA area for the next three months
- Have a phone number at which they can be reached for the next three months
- Has a primary care visit for themselves on the date of recruitment and enrollment
- Has a primary care visit with a regular clinic provider on the date of recruitment and enrollment
- English or Spanish-speaking
- Report of drug use in the previous 90 days (i.e., cocaine or amphetamines), and has an ASSIST score between 4 and 26 indicating 'at risk' drug use
- Accessible by telephone where they can be contacted over time during the study (to conduct follow-up health education phone calls)
- Able (not cognitively impaired) and willing to cooperate with data collection and research procedures, including 2 telephone counseling sessions and 2-week, 6-week, and 3-month follow-up assessments
- Planning to be in the Los Angeles area for the next 3 months so they can complete the study period
Clinicians • Regular staff primary care clinicians of our study clinics
Mexico Sites: Inclusion Criteria
Patients
- Adult men and women 18 and older receiving care at the study clinics
- Will be living in the Tijuana area for the next three months
- Have a phone number at which they can be reached for the next three months
- Has a primary care visit for themselves on the date of recruitment and enrollment
- Has a primary care visit with a regular clinic provider on the date of recruitment and enrollment
- Spanish-speaking
- Report of drug use in the previous 90 days (i.e., cocaine or amphetamines), and has an ASSIST score between 4 and 26 indicating 'at risk' drug use
- Accessible by telephone where they can be contacted over time during the study (to conduct follow-up health education phone calls)
- Able (not cognitively impaired) and willing to cooperate with data collection and research procedures, including 2 telephone counseling sessions and 2-week, 6-week, and 3-month follow-up assessments
- Planning to be in the Tijuana area for the next 3 months so they can complete the study period
Clinicians
• Regular staff primary care clinicians of our study clinics
Exclusion Criteria:
US Sites: Exclusion Criteria
Patients
- Pregnancy. Women who report being pregnant at the time of randomization will be excluded from participation. This latter exclusion criterion is based on the following reasons: (a) The interaction of drug use (in any amount) and fetal-maternal health is physiologically complex and beyond the scope of this proposed intervention. (b) Drug users who are pregnant are considered high-risk pregnancies and will likely be lost to follow-up during the study as they will be promptly referred by their primary care clinician to an obstetrician per usual clinic protocol. However, enrolled patients who become pregnant after the intervention will not be withdrawn. Their eventual exits from the study will be counted as drop-outs and will be included as "no change" in our "intent to treat" analysis. Finally, (c) a tailored brief intervention protocol for pregnant women may require more than simple clinician advice and a 2-session phone health education program. Such an intervention would be more effective if designed around the activities of prenatal care. Previous RCTs of problem alcohol use targeting healthy adults have excluded patients who are pregnant.8,9
- Homeless status. The clinics we have chosen have large numbers of homeless patients. Since this is a study on the general poverty population, we are asking homeless status in order to avoid over-sampling homeless patients. We will set a quota on number of homeless patients we can enroll without over-sampling these patients. If we reach this quota, we will apply homeless status as an exclusion criteria for subsequent subjects.
- Repeaters. Patients who have been screened or enrolled before will be asked a set of repeater questions. This includes a question on whether they have ever been involved in our UCLA study at the clinic before. We will also ask them a set of questions that combines aspects about the potential subject (mother's first name, father's first name, month and day of birth) that will screen them out if they screen again in the future.
- ASSIST Score: Drug Dependence. The RA will receive a message that the subject scored 27+ on all illicit drugs on the WHO ASSIST (i.e. indication of possible substance dependence/addiction). The RA will inform the patient that they are at risk for certain health behaviors and ask the patient if they want to disclose this information to their doctor. If they agree to disclose information to their doctor then we will fill out a letter informing the doctor of patient's dependence on specific drugs. We will also provide the patient with a list of local substance abuse treatment referrals. Please see Appendix A for copies of these referrals (Appendix A. Los Angeles County Substance Abuse Treatment Facilities).
- From Date of Screening Subject Enrolled in a Drug Treatment Facility. Subjects enrolled in a treatment program are excluded from the study. These subjects show commitment to the treatment program. Moreover, these program would serve as a competing intervention to ours, biasing the potential effect of our intervention.
Clinicians • No exclusion criteria apply to clinicians
Mexico Sites: Exclusion Criteria
Patients
- Pregnancy. Women who report being pregnant at the time of randomization will be excluded from participation. This latter exclusion criterion is based on the following reasons: (a) The interaction of drug use (in any amount) and fetal-maternal health is physiologically complex and beyond the scope of this proposed intervention. (b) Drug users who are pregnant are considered high-risk pregnancies and will likely be lost to follow-up during the study as they will be promptly referred by their primary care clinician to an obstetrician per usual clinic protocol. However, enrolled patients who become pregnant after the intervention will not be withdrawn. Their eventual exits from the study will be counted as drop-outs and will be included as "no change" in our "intent to treat" analysis. Finally, (c) a tailored brief intervention protocol for pregnant women may require more than simple clinician advice and a 2-session phone health education program. Such an intervention would be more effective if designed around the activities of prenatal care. Previous RCTs of problem alcohol use targeting healthy adults have excluded patients who are pregnant.
- Homeless status. The clinics we have chosen have large numbers of homeless patients. Since this is a study on the general poverty population, we are asking homeless status in order to avoid over-sampling homeless patients. We will set a quota on number of homeless patients we can enroll without over-sampling these patients. If we reach this quota, we will apply homeless status as an exclusion criteria for subsequent subjects.
- Repeaters. Patients who have been screened or enrolled before will be asked a set of repeater questions. This includes a question on whether they have ever been involved in the Living Well study at the clinic before. We will also ask them a set of questions that combines aspects about the potential subject (mother's first name, father's first name, month and day of birth) that will screen them out if they screen again in the future.
- ASSIST Score: Drug Dependence. The RA will receive a message that the subject scored 27+ on all illicit drugs on the WHO ASSIST (i.e. indication of possible substance dependence/addiction). The RA will inform the patient that they are at risk for certain health behaviors and ask the patient if they want to disclose this information to their doctor. If they agree to disclose information to their doctor then we will fill out a letter informing the doctor of patient's dependence on specific drugs. We will also provide the patient with a list of local substance abuse treatment referrals.
- From Date of Screening Subject Enrolled in a Drug Treatment Facility. Subjects enrolled in a treatment program are excluded from the study. These subjects show commitment to the treatment program. Moreover, these program would serve as a competing intervention to ours, biasing the potential effect of our intervention.
Clinicians
• No exclusion criteria apply to clinicians
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Intervention
The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
|
The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles.
The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
다른 이름들:
|
|
간섭 없음: Control
Usual care and a health education booklet and video on cancer prevention
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Change from Baseline Self-reported number of drug-free days at 3 months
기간: Past 30 and 90 days
|
Past 30 and 90 days
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 수석 연구원: Lillian Gelberg, MD, MSPH, University of California, Los Angeles
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2013년 2월 1일
기본 완료 (실제)
2014년 2월 1일
연구 완료 (실제)
2014년 2월 1일
연구 등록 날짜
최초 제출
2013년 9월 6일
QC 기준을 충족하는 최초 제출
2013년 9월 10일
처음 게시됨 (추정)
2013년 9월 16일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2015년 1월 12일
QC 기준을 충족하는 마지막 업데이트 제출
2015년 1월 8일
마지막으로 확인됨
2015년 1월 1일
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- BINAT 3P30DA027
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
약물 사용에 대한 임상 시험
-
University Hospitals Cleveland Medical CenterWashington University School of Medicine; Case Western Reserve University; Papua New Guinea... 그리고 다른 협력자들완전한Mass Drug Administration에 의한 림프 사상충증 제거 | 림프 사상충증에 대한 대량 의약품 관리의 모니터링 및 평가 | 림프 사상충증에 대한 대량 의약품 허가 승인파푸아 뉴기니
Quit Using Drugs Intervention Trial에 대한 임상 시험
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); Medical University of South Carolina; University...모집하지 않고 적극적으로